Reply to 'Rituximab activity in CD20-positive multiple myeloma'

Leukemia

Volumn 22, Issue 5, 2008, Pages 1083-

  Gozzetti, A ^a   Fabbri, A ^a   Lazzi, S ^a   Bocchia, M ^a   Lauria, F ^a  

^a UNIVERSITY OF SIENA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CD20 ANTIGEN; CYTOTOXIC AGENT; RITUXIMAB;

BONE MARROW CELL; CANCER IMMUNOTHERAPY; CANCER RECURRENCE; COMBINATION CHEMOTHERAPY; DRUG EFFICACY; DRUG POTENTIATION; FOLLOW UP; HUMAN; LETTER; MAINTENANCE THERAPY; MINIMAL RESIDUAL DISEASE; MONOTHERAPY; MULTIPLE MYELOMA; PLASMA CELL; PRIORITY JOURNAL;

EID: 43749108158     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/sj.leu.2405011     Document Type: Letter

References (2)